**Title**

Plasma Choline Metabolites and Colorectal Cancer Risk in the Women's Health Initiative Observational Study

**Permalink**

https://escholarship.org/uc/item/7d85t1q2

**Journal**

Cancer Research, 74(24)

**ISSN**

0008-5472

**Authors**

Bae, Sajin
Ulrich, Cornelia M
Neuhouser, Marian L
et al.

**Publication Date**

2014-12-15

**DOI**

10.1158/0008-5472.can-14-1835

Peer reviewed

# Plasma choline metabolites and colorectal cancer risk in the Women's Health Initiative Observational Study

**Sajin Bae**[1], **Cornelia M. Ulrich**[2,3,*], **Marian L. Neuhouser**[2], **Olga Malysheva**[1], **Lynn B. Bailey**[4], **Liren Xiao**[2], **Elissa C. Brown**[2], **Kara L. Cushing-Haugen**[2], **Yingye Zheng**[2], **Ting-Yuan David Cheng**[2], **Joshua W. Miller**[5,6], **Ralph Green**[6], **Dorothy S. Lane**[7], **Shirley A. A. Beresford**[2], and **Marie A. Caudill**[1,*]

[1]Division of Nutritional Sciences, Cornell University, Ithaca, NY

[2]Fred Hutchinson Cancer Research Center, Seattle, WA

[3]German Cancer Research Center and National Center for Tumor Diseases, Heidelberg, Germany

[4]Department of Foods and Nutrition, University of Georgia, Athens, GA

[5]Department of Nutritional Sciences, Rutgers University, New Brunswick, NJ

[6]Department of Medical Pathology and Laboratory Medicine, University of California, Davis, CA

[7]Department of Preventive Medicine, Stony Brook University School of Medicine, Stony Brook, NY

## Abstract

Few studies have examined associations between plasma choline metabolites and risk of colorectal cancer (CRC). Therefore, we investigated associations between plasma biomarkers of choline metabolism [choline, betaine, dimethylglycine and trimethylamine *N*-oxide (TMAO)] and CRC risk among postmenopausal women in a case-control study nested within the Women's Health Initiative Observational Study. We selected 835 matched case-control pairs, and cases were further stratified by tumor site (proximal, distal, or rectal) and stage (local/regional or metastatic). CRC was assessed by self-report and confirmed by medical records over the mean 5.2y of follow-up. Baseline plasma choline metabolites were measured by liquid chromatography-tandem mass spectrometry. In multivariable-adjusted conditional logistic regression models, plasma choline tended to be positively associated with rectal cancer risk [OR (95% CI)$_{highest\ vs.\ lowest\ quartile}$=2.44 (0.93–6.40);*P*-trend=0.08], while plasma betaine was inversely associated with CRC overall [0.68 (0.47–0.99);*P*-trend=0.01] and with local/regional tumors [0.64 (0.42–0.99);*P*-trend=0.009]. Notably, the plasma betaine:choline ratio was inversely associated with CRC overall [0.56 (0.39–0.82);*P*-trend=0.004] as well as with proximal [0.66 (0.41–1.06);*P*-trend=0.049], rectal [0.27 (0.10–0.78);*P*-trend=0.02] and local/regional [0.50 (0.33–0.76);*P*-trend=0.001] tumors. Finally, plasma TMAO, an oxidative derivative of choline produced by intestinal bacteria, was positively

---

[*]Dual senior authors and correspondence to: Marie A. Caudill: 228 Savage Hall, Cornell University, Ithaca, NY 14850; Tel: 607-254-7456; Fax: 607-255-1033; mac379@cornell.edu. Cornelia M. Ulrich: German Cancer Research Center, Im Neuenheimer Feld 460, Heidelberg 69120, Germany; Tel: +49-6221-56-5528/-5230; Fax: +49-6221-56-5231; neli.ulrich@nct-heidelberg.de.

**Conflict of Interest:** The authors state no conflict of interest in this study.

associated with rectal cancer [3.38 (1.25–9.16);*P*-trend=0.02] and with overall CRC risk among women with lower (vs. higher) plasma vitamin B12 levels (*P*-interaction=0.003). Collectively, these data suggest that alterations in choline metabolism, which may arise early in disease development, may be associated with higher risk of CRC. The positive association between plasma TMAO and CRC risk is consistent with an involvement of the gut microbiome in CRC pathogenesis.

## Keywords

Choline; betaine; trimethylamine *N*-oxide; colorectal cancer; postmenopausal women

## INTRODUCTION

Colorectal cancer (CRC) is the third most commonly diagnosed cancer in both men and women and a major cause of cancer deaths in the US (1). Disturbances in one-carbon metabolism, which lead to genomic instability (e.g., aberrant DNA methylation and DNA damage), may contribute to CRC development (2, 3). Choline and folate are methyl nutrients involved in one-carbon metabolism and play a critical role in methylation reactions, including DNA methylation, as well as DNA stability and repair (4–6). While low folate intake and low circulating levels of folate are associated with high risk of CRC (2, 7–9), less is known about the association between choline and CRC risk.

Choline participates in methylation reactions following its oxidation to betaine, which donates a methyl group for homocysteine remethylation, forming methionine and dimethylglycine (DMG). Betaine also serves as an osmolyte and plays a major role in protecting cells from hyperosmotic stress that can lead to chronic inflammation, a risk factor for CRC (1, 10, 11). To date, only a few studies have examined the association between plasma betaine and colorectal carcinogenesis. In a Norwegian population, plasma betaine was inversely associated with the occurrence of distal colorectal adenomas (12). A recent case-control study nested within the European Prospective Investigation into Cancer and Nutrition (EPIC) also reported an inverse association between plasma betaine and CRC risk among participants with low plasma folate concentrations (13).

Choline can also undergo catabolism by the intestinal bacteria to form trimethylamine (TMA), which is further converted to trimethylamine *N*-oxide (TMAO) by the liver enzyme flavin monooxygenase (FMO) (14, 15). Although intestinal microbiota has been implicated in the development of CRC (16–18), the association between gut microbiota-dependent choline metabolites and CRC risk is unknown.

In this report, we investigated the associations between plasma biomarkers of choline metabolism (choline, betaine, DMG and TMAO) and CRC risk in a case-control study nested within the Women's Health Initiative Observational Study (WHI-OS) cohort. Due to the interdependence of choline and folate as well as other B-vitamins (vitamin B6 and B12) in one-carbon metabolism (4, 5), we further explored their influence and that of folic acid (FA) fortification (19) on the associations between plasma choline metabolites and CRC risk.

# MATERIALS AND METHODS

## Study population

The WHI-OS is a prospective cohort study to investigate the predictors and causes of morbidity and mortality in postmenopausal women (20, 21). The study enrolled 93,676 postmenopausal women, aged 50–79 y, at 40 centers throughout the US between 1993 and 1998. Women were excluded if they had medical conditions with a predicted survival of <3 y; if they had adherence/retention issues; or if they were participating in another clinical trial.

For the present study, incident CRC cases were selected as of April 24 2008, and the average time from baseline to CRC diagnosis was $5.2 \pm 3.1$ y (mean $\pm$ SD) (11, 22). Women were excluded if they had a history of CRC or in situ CRC; if they had no available biospecimens; or if a death certificate provided the only report of CRC. Controls who were free of cancer at the time of case diagnosis were selected from the WHI-OS by using risk-set sampling. Cases and controls were matched on age ($\pm 3$ y), race/ethnicity, timing of baseline blood draw ($\pm 6$ months), enrollment date ($\pm 1$ y) and baseline hysterectomy status (11, 22). Thus, the present study included 835 incident CRC cases and 835 matched controls. Approval for conducting the study was obtained from human subject review committees at the Fred Hutchinson Cancer Research Center (WHI Clinical Coordinating Center), as well as at all 40 clinical centers. Written informed consent was obtained from all participants.

## Data collection

Demographic and health-related characteristics were collected at baseline using standardized questionnaires (20). Height and weight were measured using a standardized protocol, and body mass index (BMI) was calculated as weight (kg)/height ($m^2$). CRC was annually assessed using self-administered questionnaires collected from each participant by mail and during an in-person clinical follow-up visit at year 3 (23). All CRC cases were confirmed by physician adjudicators. The International Classification of Diseases for Oncology, second edition codes were used to identify CRC cases based on tumor site as previously described (11). The Surveillance Epidemiology and End Results (SEER) program guidelines of the National Cancer Institute were used for classifications of cancer cases (23).

## Analytic measurements

Blood samples were drawn at study baseline after at least 12 hours of fasting. Samples were kept at 4°C for up to 1 hour prior to centrifugation. Plasma and serum were collected and stored at −70°C until analysis (22). Plasma concentrations of choline and its metabolites (betaine, DMG, and TMAO) were measured in de-identified samples using liquid chromatography-tandem mass spectrometry methodology with modifications based on our instrumentation (24). Plasma and red blood cell (RBC) folate as well as plasma vitamin B12 were measured by radioassays (SimulTRAC; MP Biomedicals); plasma pyridoxal-5′-phosphate (PLP) was analyzed by high-pressure liquid chromatography (HPLC) with fluorescence detection (25); and total plasma homocysteine was determined by HPLC with post-column fluorescence detection (26). Inter-assay coefficients of variance of the blind duplicate control samples for each of the assays were as follows: choline, 7%; betaine, 5%;

DMG, 9%; TMAO, 6%; plasma folate, 5%; RBC folate, 10%; vitamin B12, 6%; PLP, 6%; and homocysteine, 7%.

## Statistical analysis

Baseline characteristics of CRC cases and controls were compared using (i) t tests for normally distributed continuous variables; (ii) Wilcoxon tests for non-normally distributed continuous variables; and (iii) chi-square tests for categorical variables. Associations among plasma concentrations of choline metabolites were assessed using Spearman correlation analysis. Plasma choline metabolites were divided into quartiles based on the distribution of the controls. Conditional logistic regression models were used to estimate odds ratios (ORs) and 95% confidence intervals (CIs) of CRC risk among quartiles of choline metabolites, using the lowest quartiles as reference groups. Because risk-set sampling was used for selecting matched controls, the conditional ORs yielded estimates of the incidence rate ratio in a full cohort study. We further explored the associations between the ratios of choline metabolites (i.e., betaine:choline, DMG:choline and DMG:betaine) and CRC risk, because the ratios of these metabolites (vs. individual metabolite alone) are suggested to be stronger predictors of metabolic disturbances (27). The models were first adjusted only for age (continuous) and then further adjusted for baseline confounding factors selected a priori: BMI, pack-years of smoking, physical activity, use of postmenopausal hormone therapy, history of colonoscopy, RBC folate, plasma vitamin B12, PLP and homocysteine. All of these factors were added in the model as continuous variables except for postmenopausal hormone therapy use (categorical: never, past or current). Tests of linear trend across increasing quartiles of choline metabolites were conducted by the Wald test, using the median value for each quartile as a single continuous variable.

To explore whether the associations between choline metabolites and CRC risk were modified by B-vitamins involved in one-carbon metabolism, we conducted analyses stratified into high/low plasma concentrations of folate, PLP and vitamin B12 based on median values among controls. We also examined the influence of FA fortification by stratifying into the following FA fortification periods based on the timing of baseline blood draw: pre-fortification (1994–1995), peri-fortification (1996–1997; when initial fortification began, but was not yet mandated), and post-fortification (1998) (28). The Wald test was used to evaluate the effect modification including a 2-way interaction term between the ordinal trend variables (choline metabolites) and effect modifiers (B-vitamins or FA fortification period). Because the matching was broken, unconditional multiple logistic regression models were used in these stratified analyses, further adjusting for days to CRC diagnosis and ethnicity. Significance was defined as *P*<0.05, and all statistical tests were 2-sided. Analyses were conducted by SAS version 9.3 (SAS Institute Inc).

# RESULTS

## Characteristics of the study population

Baseline characteristics of the CRC cases and controls are shown in Table 1. Compared to the controls, the cases had a higher BMI, a greater number of cigarettes smoked among current smokers, fewer weekly minutes of moderate or strenuous physical activity, and had a

different distribution pattern of postmenopausal hormone therapy use. The CRC group also had a lower percentage of previous colonoscopy, but a higher percentage of having history of a colon polyp removed.

Plasma choline, betaine and DMG concentrations did not differ between cases and controls (Table 1). However, the cases (vs. controls) had higher ($P$=0.005) median plasma concentrations of TMAO (4.0 vs. 3.8 μmol/L) and tended to have a lower ($P$=0.07) mean plasma betaine:choline ratio (2.9 vs. 3.0). In addition, the cases had lower median plasma folate, PLP and vitamin B12 as well as higher median plasma homocysteine.

Among the cases, tumors were classified by tumor site (proximal, distal, or rectal) and stage (local/regional or metastatic). More than half (59%; n=489) of the tumors were proximal followed by distal (21%; n=177) and rectal (19%; n=155). Two percent (n=14) of the tumors were not classified by tumor site because they were unknown or had overlapping lesions. In addition, when stratified by tumor stage, the majority of the cases (85%; n=712) had localized or regional tumors, whereas 12% of the cases (n=104) had distant metastases. Two percent (n=18) of the tumors were not stratified by tumor stage because their stages were unknown or not determined.

## Correlations among plasma concentrations of choline metabolites

Spearman correlation coefficients (r) were computed to examine associations among plasma choline metabolites. There were statistically significant, but modest, positive associations of plasma choline with plasma betaine (r=0.22; $P$<0.001), DMG (r=0.21; $P$<0.001) and TMAO (r=0.18; $P$<0.001). Plasma betaine was also positively correlated with plasma DMG (r=0.39; $P$<0.001).

## Associations between plasma choline metabolites and CRC risk

In multivariable-adjusted analyses, women in the highest (vs. lowest) choline quartile were at an estimated 2.4 times greater risk of rectal cancer [$P$-trend=0.08] (Table 2). Conversely, women in the highest (vs. lowest) betaine quartile were at 32% lower CRC risk overall [OR (95% CI)$_{highest vs. lowest quartile}$=0.68 (0.47–0.99); $P$-trend=0.01], 36% lower risk of local/ regional tumors [0.64 (0.42–0.99); $P$-trend=0.009] and 31% lower risk of proximal tumors [0.69 (0.43–1.10); $P$-trend=0.05] (Table 3). No association between DMG quartiles and CRC risk was observed (Supplementary Table S1).

Notably, after controlling for covariates, women in the highest (vs. lowest) quartile of the plasma betaine:choline ratio were at an estimated 44% lower CRC risk overall [0.56 (0.39–0.82); $P$-trend=0.004] as well as 34% lower risk of proximal tumors [0.66 (0.41–1.06); $P$-trend=0.049], 73% lower risk of rectal tumors [0.27 (0.10–0.78); $P$-trend=0.02] and 50% lower risk of local/regional tumors [0.50 (0.33–0.76); $P$-trend=0.001] (Table 4). The plasma DMG:choline ratio tended to be inversely associated with CRC risk overall [0.69 (0.48–0.98); $P$-trend=0.06] (Supplementary Table S2). The inverse association was statistically significant for local/regional tumors [0.62 (0.42–0.91); $P$-trend=0.04] and borderline significant for proximal tumors [0.57 (0.36–0.93); $P$-trend=0.07]. Last, the DMG:betaine

ratio tended to be positively associated with rectal cancer risk [2.56 (0.98–6.64); *P*-trend=0.09] (Supplementary Table S3).

Plasma TMAO, an oxidative derivative of choline produced by intestinal bacteria, was positively associated with CRC risk in age-adjusted analyses [1.78 (1.32–2.40); *P*-trend=0.005] (Table 5). Women in the highest (vs. lowest) TMAO quartile were at approximately 1.9 times greater risk of proximal tumors [*P*-trend=0.04], 2.3 times greater risk of rectal tumors [*P*-trend=0.02] and 1.8 times greater risk of local/regional tumors [*P*-trend=0.008]. After controlling for covariates, the positive association remained strong and statistically significant for rectal cancer with approximately 3.4 times greater risk among women in the highest (vs. lowest) TMAO quartile [*P*-trend=0.02]. The borderline significant positive association was also observed for local/regional tumors with approximately 1.8 times greater risk in the highest (vs. lowest) TMAO quartile [*P*-trend=0.08]. Notably, although the linear trend across TMAO quartiles was not statistically significant, higher risk was observed from the second (vs. lowest) quartile of TMAO for CRC overall [1.90 (1.36–2.64)] and for proximal tumors [2.37 (1.52–3.70)]. Similarly, women in the second (vs. lowest) quartile of TMAO were at an estimated 1.9 times higher risk for local/regional tumors and 3.6 times higher risk for metastatic tumors, but this was not consistently observed in the other quartiles.

## Associations of choline metabolites with CRC risk according to plasma B-vitamin concentrations

To further explore whether B-vitamins (folate, PLP and vitamin B12) modified the associations between choline metabolites and CRC risk, we stratified into high/low plasma concentrations of B-vitamins and assessed the interaction. After controlling for covariates, vitamin B12 status modified the association between plasma TMAO and CRC risk (*P*-interaction=0.003) (Table 6). Specifically, higher CRC risk was observed with higher TMAO quartiles among women with low plasma vitamin B12 (i.e.,  505 pg/mL) [*P*-trend=0.001], but not among those with high B12 levels. Other than this finding, no effect modifications by B-vitamins were observed on the associations of plasma choline metabolites and their ratios with CRC risk (data not shown).

## Associations of choline metabolites with CRC risk according to FA fortification period

We next explored the possible effect modification by FA fortification. The association of plasma choline, DMG, TMAO and the ratios of choline metabolites with CRC risk did not differ by fortification periods (data not shown). However, after controlling for covariates, plasma betaine tended to interact with FA fortification period in association with CRC risk (*P*-interaction=0.08) (Table 7). Specifically, lower CRC risk was observed with higher plasma betaine during the pre-[*P*-trend=0.02] and peri-[*P*-trend=0.02] fortification periods, but not during the post-fortification period.

## DISCUSSION

To the best of our knowledge, this is the first study to assess associations between plasma biomarkers of choline metabolism and CRC risk among postmenopausal women in the US.

The following main findings emerged: 1) plasma choline (modest positive) and betaine (inverse) were divergently associated with CRC risk; 2) the plasma betaine:choline ratio was more strongly associated with CRC risk than was either metabolite alone; and 3) higher plasma TMAO concentrations were associated with higher risk of CRC especially among women with low plasma vitamin B12.

The divergent associations of plasma choline and betaine with CRC risk are unexpected given that betaine is derived from choline and increases in response to a higher choline intake (24). Thus, the divergent associations may arise from the disease process itself which could alter choline metabolism prior to diagnosis (29, 30). For example, postmenopausal women harboring undiagnosed, precancerous lesions may have a higher demand for choline due to its greater use for membrane biosynthesis by abnormally dividing cells (31, 32). This in turn may upregulate de novo choline production through the hepatic phosphatidylethanolamine *N*-methyltransferase (PEMT) pathway. Enhanced hepatic PEMT activity would be expected to elevate choline, a product of the PEMT reaction, while depleting betaine, a source of methyl groups for the PEMT reaction. This metabolic scenario is observed during pregnancy (33), which like cancer is a state of rapidly dividing cells and exhibits several of the same molecular characteristics (34). However, unlike pregnancy where providing substrate for the PEMT reaction may beneficially influence fetal growth and development, betaine supplementation for the purposes of CRC reduction among postmenopausal women appears unwise because the prevalence of colonic neoplasia increases with age (35) and extra betaine may accelerate tumor progression.

The divergent associations of plasma choline and betaine with CRC risk observed in our study cohort differ from findings of a recent case-control study nested within the EPIC cohort, where, in the subgroup analyses of women, plasma choline (but not plasma betaine) was inversely associated with CRC risk (13). One major difference between the study cohorts that could explain these discordant findings is folate status. Specifically, median plasma folate concentrations were approximately 3.5 times higher in the WHI (vs. EPIC) cohort. Other contributing factors may include age of participants, follow-up period, blood sample collection (fasting vs. non-fasting), use of different cutpoints for categories of choline metabolites and the status of other nutrients involved in one-carbon metabolism.

In the present study, the plasma betaine:choline ratio was more strongly associated with CRC risk than either metabolite alone. After adjusting for potential confounders, women in the highest (vs. lowest) betaine:choline quartile were at 44% lower CRC risk overall, 34% lower proximal tumors, 50% lower local/regional tumors and 73% lower rectal tumors. The association between the betaine:choline ratio and CRC risk did not appear to differ according to B-vitamin status or FA fortification period. In contrast, FA exposure appeared to modify the association between plasma betaine and CRC risk with an inverse association observed in the pre- and peri-fortification periods, but not in the post-fortification period. As such, the association between plasma betaine and CRC risk appears to be dependent on folate availability and may be more evident when folate availability is low (i.e., prior to FA fortification). Overall, these data support the utility of the plasma betaine:choline ratio as a potential biomarker for excess risk of CRC in postmenopausal women.

In humans, choline can undergo catabolism by anaerobic intestinal bacteria to produce TMA, which is further converted to TMAO by the hepatic enzyme FMO (14, 15). Similarly, L-carnitine also serves as a precursor of TMAO through a gut microbiota-dependent metabolism (i.e., choline/carnitine → gut microbiota → TMA/TMAO) (36, 37). This metabolic pathway mediated by intestinal microbiota has been linked to several diseases (37–41), suggesting the potential role of gut-microbial metabolism and their metabolic products in carcinogenesis among humans. The present study, for the first time to our knowledge, examined an association between circulating concentrations of TMAO and CRC risk. We found that women in the highest (vs. lowest) TMAO quartile had ~3.4 times greater risk of rectal cancer. Although no statistically significant linear trend was observed, increased risk was also detected from the second quartile of TMAO with 1.9 times greater risk for CRC overall and for local/regional tumors, ~2.4 times greater risk for proximal tumors, and ~3.6 times greater risk for metastatic tumors. These findings collectively suggest that plasma TMAO may serve as a potential predictor of increased CRC risk.

Alterations in the intestinal microbiota may predispose to the development and progression of CRC through affecting multiple processes, including colonic epithelial cell proliferation, immune system, and chronic inflammation (16, 18). For example, compared to healthy individuals, increased number and diversity as well as the decreased stability of a colonic bacterial group, *Clostridium*, have been characterized in patients with CRC (16, 42). Indeed, *Clostridium* is also suggested to play a role in the conversion of choline (41, 43) and carnitine (37, 44) to TMA, thereby contributing to TMAO production. Thus, it is possible that the positive association between plasma TMAO and CRC risk may arise from abnormal changes in particular colonic bacteria, which could occur early in disease development prior to diagnosis. Given that TMAO is a gut bacteria-derived metabolite, it may also represent evidence for an etiologic correlation between intestinal microbiota and CRC and could potentially serve as a novel biomarker of CRC risk.

Notably, the association between plasma TMAO and CRC risk appeared to be modified by vitamin B12 status. Specifically, the risk of CRC increased across increasing TMAO quartiles in the low B12 group, but not in the high B12 group. These data suggest that postmenopausal women with higher TMAO and lower vitamin B12 may be more susceptible to developing CRC. Certain groups of intestinal bacteria can synthesize (45, 46) and consume (47, 48) vitamin B12, which may impact the vitamin B12 requirement/status of the host. Indeed, overgrowth of intestinal bacteria that take up vitamin B12 has been implicated in B12 malabsorption (47–50). In human intestine, overgrowth of a specific bacterial group can also block colonization of other bacterial groups (16), yielding an imbalance between their metabolic production and consumption. Therefore, elevated CRC risk among women with high TMAO and low vitamin B12 may in part be associated with the disturbances in colonic bacterial populations. Additional studies are required to confirm these findings, and potential biologic mechanisms need further elucidation.

Key strengths of the present study include: (i) the prospective design; (ii) the large sample size, which allowed for stratified analyses by tumor site/stage as well as by B-vitamins and FA fortification periods; and (iii) assessment of choline metabolite ratios (especially betaine:choline ratio), which provided more robust CRC risk estimates. Several limitations

should also be noted: (i) although we attempted to control confounding, there is a potential for residual confounding by factors that were either not collected in the WHI-OS or not measured with sufficient precision; (ii) although the concentrations of plasma choline and its metabolites are stable through time in healthy women (24), single measures of these metabolites may not fully reflect long-term associations with CRC risk; and (iii) although baseline hysterectomy status was used as a matching factor based on the evidence that female sex hormones (e.g., estrogen) are associated with CRC risk (51–53), it may not comprehensively account for estrogen status. However, this would not be expected to have an influence on the results, as the analyses were adjusted for the use of postmenopausal hormone therapy (which would more comprehensively account for estrogen status).

In conclusion, the results of this study indicate that alterations in choline metabolism, which may arise early in disease development, associate with higher risk of CRC in postmenopausal women. Our data also indicate that the plasma betaine:choline ratio may be a potential indicator of CRC risk, which, if confirmed, could have clinical implications for CRC screening. This study also provides new evidence that plasma TMAO, an oxidative derivative of choline produced by intestinal bacteria, may serve as a potential biomarker for increased risk of CRC especially among those with low plasma vitamin B12 concentrations. Although further investigations are needed to delineate the underlying mechanisms, these novel findings may advance understanding of an etiologic correlation between intestinal bacteria and CRC pathogenesis.

## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

## Acknowledgments

## References

1. Haggar FA, Boushey RP. Colorectal cancer epidemiology: incidence, mortality, survival, and risk factors. Clin Colon Rectal Surg. 2009; 22:191–7. [PubMed: 21037809]

2. Choi SW, Mason JB. Folate status: effects on pathways of colorectal carcinogenesis. J Nutr. 2002; 132:2413S–2418S. [PubMed: 12163703]

3. Davis CD, Uthus EO. DNA methylation, cancer susceptibility, and nutrient interactions. Exp Biol Med. 2004; 229:988–95.

4. Mason JB. Biomarkers of nutrient exposure and status in one-carbon (methyl) metabolism. J Nutr. 2003; 133:941S–947S. [PubMed: 12612180]

5. Caudill, MA. Folate and choline interrelationships: metabolic and potential health implications. In: Bailey, LB., editor. Folate in health and disease. Florida: CRC Press; 2009. p. 449-65.

6. Crider KS, Yang TP, Berry RJ, Bailey LB. Folate and DNA methylation: a review of molecular mechanisms and the evidence for folate's role. Adv Nutr. 2012; 3:21–38. [PubMed: 22332098]

7. Giovannucci E. Epidemiologic studies of folate and colorectal neoplasia: a review. J Nutr. 2002; 132:2350S–2355S. [PubMed: 12163691]

8. Pufulete M, Al-Ghnaniem R, Leather AJ, Appleby P, Gout S, Terry C, et al. Folate status, genomic DNA hypomethylation, and risk of colorectal adenoma and cancer: a case control study. Gastroenterology. 2003; 124:1240–8. [PubMed: 12730865]

9. Kim YI. Folate and DNA methylation: a mechanistic link between folate deficiency and colorectal cancer? Cancer Epidemiol Biomarkers Prev. 2004; 13:511–9. [PubMed: 15066913]

10. Brocker C, Thompson DC, Vasiliou V. The role of hyperosmotic stress in inflammation and disease. Biomol Concepts. 2012; 3:345–64. [PubMed: 22977648]

11. Toriola AT, Cheng TY, Neuhouser ML, Wener MH, Zheng Y, Brown E, et al. Biomarkers of inflammation are associated with colorectal cancer risk in women but are not suitable as early detection markers. Int J Cancer. 2013; 132:2648–58. [PubMed: 23161620]

12. de Vogel S, Schneede J, Ueland PM, Vollset SE, Meyer K, Fredriksen A, et al. Biomarkers related to one-carbon metabolism as potential risk factors for distal colorectal adenomas. Cancer Epidemiol Biomarkers Prev. 2011; 20:1726–35. [PubMed: 21693628]

13. Nitter M, Norgård B, de Vogel S, Eussen SJPM, Meyer K, Ulvik A, et al. Plasma Methionine, Choline, Betaine, and Dimethylglycine, in relation to Colorectal Cancer Risk in the European Prospective Investigation into Cancer and Nutrition (EPIC). Ann Oncol. 2014 [Epub ahead of print].

14. Zeisel SH, daCosta KA, Youssef M, Hensey S. Conversion of dietary choline to trimethylamine and dimethylamine in rats: dose-response relationship. J Nutr. 1989; 119:800–4. [PubMed: 2723829]

15. Krueger SK, Williams DE. Mammalian flavin-containing monooxygenases: structure/function, genetic polymorphisms and role in drug metabolism. Pharmacol Ther. 2005; 106:357–87. [PubMed: 15922018]

16. Scanlan PD, Shanahan F, Clune Y, Collins JK, O'Sullivan GC, O'Riordan M, et al. Culture-independent analysis of the gut microbiota in colorectal cancer and polyposis. Environ Microbiol. 2008; 10:789–98. [PubMed: 18237311]

17. Davis CD, Milner JA. Gastrointestinal microflora, food components and colon cancer prevention. J Nutr Biochem. 2009; 20:743–52. [PubMed: 19716282]

18. Zhu Q, Gao R, Wu W, Qin H. The role of gut microbiota in the pathogenesis of colorectal cancer. Tumour Biol. 2013; 34:1285–300. [PubMed: 23397545]

19. US Food and Drug Administration. Food standards: amendment of standards of identity for enriched grain products to require addition of folic acid. Final Rule. 21 CFR Parts 136, 137, and 139. Fed Regist. 1996; 61:8781–97.

20. The Women's Health Initiative Study Group. Design of the Women's Health Initiative clinical trial and observational study. Control Clin Trials. 1998; 19:61–109. [PubMed: 9492970]

21. Langer RD, White E, Lewis CE, Kotchen JM, Hendrix SL, Trevisan M. The Women's Health Initiative Observational Study: baseline characteristics of participants and reliability of baseline measures. Ann Epidemiol. 2003; 13:S107–21. [PubMed: 14575943]

22. Miller JW, Beresford SA, Neuhouser ML, Cheng TY, Song X, Brown EC, et al. Homocysteine, cysteine, and risk of incident colorectal cancer in the Women's Health Initiative observational cohort. Am J Clin Nutr. 2013; 97:827–34. [PubMed: 23426034]

23. Curb JD, McTiernan A, Heckbert SR, Kooperberg C, Stanford J, Nevitt M, et al. Outcomes ascertainment and adjudication methods in the Women's Health Initiative. Ann Epidemiol. 2003; 13:S122–8. [PubMed: 14575944]

24. Yan J, Jiang X, West AA, Perry CA, Malysheva OV, Devapatla S, et al. Maternal choline intake modulates maternal and fetal biomarkers of choline metabolism in humans. Am J Clin Nutr. 2012; 95:1060–71. [PubMed: 22418088]

25. Talwar D, Quasim T, McMillan DC, Kinsella J, Williamson C, O'Reilly DS. Optimisation and validation of a sensitive high-performance liquid chromatography assay for routine measurement of pyridoxal 5-phosphate in human plasma and red cells using pre-column semicarbazide derivatisation. J Chromatogr B Analyt Technol Biomed Life Sci. 2003; 792:333–43.

26. Gilfix BM, Blank DW, Rosenblatt DS. Novel reductant for determination of total plasma homocysteine. Clin Chem. 1997; 43:687–8. [PubMed: 9105275]

27. Yan J, Winter LB, Burns-Whitmore B, Vermeylen F, Caudill MA. Plasma choline metabolites associate with metabolic stress among young overweight men in a genotype-specific manner. Nutr Diabetes. 2012; 2:e49. [PubMed: 23169489]

28. Zschabitz S, Cheng TY, Neuhouser ML, Zheng Y, Ray RM, Miller JW, et al. B vitamin intakes and incidence of colorectal cancer: results from the Women's Health Initiative Observational Study cohort. Am J Clin Nutr. 2013; 97:332–43. [PubMed: 23255571]

29. Aboagye EO, Bhujwalla ZM. Malignant transformation alters membrane choline phospholipid metabolism of human mammary epithelial cells. Cancer Res. 1999; 59:80–4. [PubMed: 9892190]

30. Glunde K, Serkova NJ. Therapeutic targets and biomarkers identified in cancer choline phospholipid metabolism. Pharmacogenomics. 2006; 7:1109–23. [PubMed: 17054420]

31. Nakagami K, Uchida T, Ohwada S, Koibuchi Y, Suda Y, Sekine T, et al. Increased choline kinase activity and elevated phosphocholine levels in human colon cancer. Jpn J Cancer Res. 1999; 90:419–24. [PubMed: 10363580]

32. Glunde K, Bhujwalla ZM, Ronen SM. Choline metabolism in malignant transformation. Nat Rev Cancer. 2011; 11:835–48. [PubMed: 22089420]

33. Yan J, Jiang X, West AA, Perry CA, Malysheva OV, Brenna JT, et al. Pregnancy alters choline dynamics: results of a randomized trial using stable isotope methodology in pregnant and nonpregnant women. Am J Clin Nutr. 2013; 98:1459–67. [PubMed: 24132975]

34. Holtan SG, Creedon DJ, Haluska P, Markovic SN. Cancer and pregnancy: parallels in growth, invasion, and immune modulation and implications for cancer therapeutic agents. Mayo Clin Proc. 2009; 84:985–1000. [PubMed: 19880689]

35. Lin OS, Kozarek RA, Schembre DB, Ayub K, Gluck M, Drennan F, et al. Screening colonoscopy in very elderly patients: prevalence of neoplasia and estimated impact on life expectancy. JAMA. 2006; 295:2357–65. [PubMed: 16720821]

36. Zhang AQ, Mitchell SC, Smith RL. Dietary precursors of trimethylamine in man: a pilot study. Food Chem Toxicol. 1999; 37:515–20. [PubMed: 10456680]

37. Koeth RA, Wang Z, Levison BS, Buffa JA, Org E, Sheehy BT, et al. Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat Med. 2013; 19:576–85. [PubMed: 23563705]

38. Dumas ME, Barton RH, Toye A, Cloarec O, Blancher C, Rothwell A, et al. Metabolic profiling reveals a contribution of gut microbiota to fatty liver phenotype in insulin-resistant mice. Proc Natl Acad Sci U S A. 2006; 103:12511–6. [PubMed: 16895997]

39. Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature. 2006; 444:1027–31. [PubMed: 17183312]

40. Wang Z, Klipfell E, Bennett BJ, Koeth R, Levison BS, Dugar B, et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature. 2011; 472:57–63. [PubMed: 21475195]

41. Loscalzo J. Lipid metabolism by gut microbes and atherosclerosis. Circ Res. 2011; 109:127–9. [PubMed: 21737814]

42. Kanazawa K, Konishi F, Mitsuoka T, Terada A, Itoh K, Narushima S, et al. Factors influencing the development of sigmoid colon cancer. Bacteriologic and biochemical studies. Cancer. 1996; 77:1701–6. [PubMed: 8608565]

43. Möller B, Hippe H, Gottschalk G. Degradation of various amine compounds by mesophilic clostridia. Arch Microbiol. 1986; 145:85–90. [PubMed: 3753143]

44. Bäckhed F. Meat-metabolizing bacteria in atherosclerosis. Nat Med. 2013; 19:533–4. [PubMed: 23652100]

45. Albert MJ, Mathan VI, Baker SJ. Vitamin B12 synthesis by human small intestinal bacteria. Nature. 1980; 283:781–2. [PubMed: 7354869]

46. LeBlanc JG, Milani C, de Giori GS, Sesma F, van Sinderen D, Ventura M. Bacteria as vitamin suppliers to their host: a gut microbiota perspective. Curr Opin Biotechnol. 2013; 24:160–8. [PubMed: 22940212]

47. Giannella RA, Broitman SA, Zamcheck N. Vitamin B12 uptake by intestinal microorganisms: mechanism and relevance to syndromes of intestinal bacterial overgrowth. J Clin Invest. 1971; 50:1100–7. [PubMed: 4994753]

48. Sherwood WC, Goldstein F, Haurani FI, Wirts CW. Studies of the small-intestinal bacterial flora and of intestinal absorption in pernicious anemia. Am J Dig Dis. 1964; 9:416–25. [PubMed: 14169408]

49. Baik HW, Russell RM. Vitamin B12 deficiency in the elderly. Annu Rev Nutr. 1999; 19:357–77. [PubMed: 10448529]

50. Nilsson-Ehle H. Age-related changes in cobalamin (vitamin B12) handling. Implications for therapy. Drugs Aging. 1998; 12:277–92. [PubMed: 9571392]

51. Chlebowski RT, Wactawski-Wende J, Ritenbaugh C, Hubbell FA, Ascensao J, Rodabough RJ, et al. Estrogen plus progestin and colorectal cancer in postmenopausal women. N Engl J Med. 2004; 350:991–1004. [PubMed: 14999111]

52. Gunter MJ, Hoover DR, Yu H, Wassertheil-Smoller S, Rohan TE, Manson JE, et al. Insulin, insulin-like growth factor-I, endogenous estradiol, and risk of colorectal cancer in postmenopausal women. Cancer Res. 2008; 68:329–37. [PubMed: 18172327]

53. Grodstein F, Newcomb PA, Stampfer MJ. Postmenopausal hormone therapy and the risk of colorectal cancer: a review and meta-analysis. Am J Med. 1999; 106:574–82. [PubMed: 10335731]

**Table 1**

Characteristics of CRC cases and controls[a]

| Characteristics | Cases | | Controls | | P value |
|---|---|---|---|---|---|
| | **n** | **Value** | **n** | **Value** | |
| Age (years)[b] | 835 | 66 ± 7 | 835 | 67 ± 7 | 0.52 |
| BMI (kg/m²)[b] | 824 | 28.2 ± 6.1 | 827 | 27.1 ± 5.9 | 0.004 |
| Race/ethnicity[c] | 835 | 100 | 835 | 100 | 1.0 |
| White | 711 | 85 | 711 | 85 | |
| Other[e] | 124 | 15 | 124 | 15 | |
| Family income ($)[c] | 801 | 100 | 793 | 100 | 0.30 |
| < 34,999 | 374 | 47 | 351 | 44 | |
| 35,000–74,999 | 294 | 37 | 282 | 36 | |
| 75,000 | 111 | 14 | 137 | 17 | |
| Do not know | 22 | 3 | 23 | 3 | |
| Education (high school or less)[c] | 160 | 19 | 186 | 22 | 0.11 |
| Residence location (US region)[c] | 835 | 100 | 835 | 100 | 0.57 |
| Northeast | 210 | 25 | 189 | 23 | |
| South | 188 | 23 | 203 | 24 | |
| Midwest | 196 | 23 | 191 | 23 | |
| West | 241 | 29 | 252 | 30 | |
| Pack-years smoking[b] | 802 | 13 ± 22 | 799 | 9 ± 17 | <0.001 |
| Moderate or strenuous activity (min/wk)[b] | 824 | 98 ± 136 | 827 | 111 ± 145 | 0.05 |
| Use of postmenopausal hormone therapy[c] | 834 | 100 | 835 | 100 | <0.001 |
| Never | 415 | 50 | 346 | 41 | |
| Past | 138 | 17 | 135 | 16 | |
| Current | 281 | 34 | 354 | 42 | |
| Family history of CRC (yes)[c] | 167 | 22 | 143 | 19 | 0.17 |
| History of colonoscopy or sigmoidoscopy (yes)[c] | 431 | 53 | 500 | 61 | <0.001 |
| History of colon polyp removal (yes)[c] | 102 | 24 | 90 | 18 | 0.03 |

| Characteristics | Cases | | Controls | | P value |
|---|---|---|---|---|---|
| | n | Value | n | Value | |
| Plasma choline (µmol/L)[b] | 835 | 9.5 ± 2.3 | 835 | 9.4 ± 2.2 | 0.25 |
| Plasma betaine (µmol/L)[b] | 835 | 26.6 ± 10.8 | 835 | 27.1 ± 10.7 | 0.31 |
| Plasma DMG (µmol/L)[d] | 835 | 2.3 (1.9–2.9) | 834 | 2.3 (1.9–2.9) | 0.89 |
| Plasma TMAO (µmol/L)[d] | 835 | 4.0 (2.9–6.0) | 835 | 3.8 (2.6–5.7) | 0.005 |
| Plasma betaine:choline ratio[b] | 835 | 2.9 ± 1.2 | 835 | 3.0 ± 1.3 | 0.07 |
| Plasma DMG:choline ratio[b] | 835 | 0.27 ± 0.12 | 834 | 0.28 ± 0.11 | 0.52 |
| Plasma DMG:betaine ratio[b] | 835 | 0.10 ± 0.05 | 834 | 0.10 ± 0.05 | 0.51 |
| Plasma folate (ng/mL)[d] | 835 | 15.6 (8.9–25.3) | 835 | 17.2 (9.9–27.1) | 0.02 |
| RBC folate (ng/mL)[d] | 832 | 564 (410–742) | 835 | 591 (431–751) | 0.16 |
| Plasma PLP (nmol/L)[d] | 821 | 60 (39–101) | 817 | 67 (44–113) | 0.002 |
| Plasma vitamin B12 (pg/mL)[d] | 833 | 477 (336–661) | 835 | 505 (376–691) | 0.02 |
| Plasma homocysteine (µmol/L)[d] | 835 | 8.1 (6.8–9.9) | 835 | 7.7 (6.7–9.4) | 0.002 |

[a] Differences between cases and controls were analyzed by t tests (normally distributed continuous variables); Wilcoxon tests (non-normally distributed continuous variables); and chi-square tests (categorical variables).

[b] Values are mean ± SD for normally distributed continuous variables.

[c] Values are percentage for categorical variables.

[d] Values are median (interquartile range) for non-normally distributed continuous variables.

[e] Black or African-American, Hispanic, Asian or Pacific Islander, American Indian or Alaskan Native, or missing.

**Table 2**

ORs (95% CIs) of CRC by quartile of plasma choline[a]

| | Quartiles of choline (µmol/L) | | | | |
| | 1 (≤7.9) | 2 (>7.9–9.2) | 3 (>9.2–10.6) | 4 (>10.6) | P-trend[b] |
|---|---|---|---|---|---|
| n | 412 | 403 | 408 | 447 | |
| **All participants** | | | | | |
| Age-adjusted | 1 | 1.06 (0.80, 1.40) | 0.96 (0.71, 1.29) | 1.30 (0.97, 1.74) | 0.09 |
| Multivariable[c] | 1 | 1.01 (0.74, 1.39) | 0.95 (0.68, 1.31) | 1.22 (0.88, 1.70) | 0.26 |
| **By tumor site** | | | | | |
| Proximal | | | | | |
| Age-adjusted | 1 | 1.16 (0.80, 1.70) | 1.11 (0.75, 1.62) | 1.33 (0.91, 1.95) | 0.17 |
| Multivariable[c] | 1 | 1.06 (0.68, 1.66) | 1.07 (0.69, 1.65) | 1.21 (0.78, 1.87) | 0.39 |
| Distal | | | | | |
| Age-adjusted | 1 | 1.02 (0.58, 1.82) | 0.69 (0.34, 1.39) | 1.12 (0.61, 2.05) | 0.73 |
| Multivariable[c] | 1 | 0.92 (0.48, 1.77) | 0.68 (0.31, 1.49) | 1.07 (0.51, 2.23) | 0.91 |
| Rectal | | | | | |
| Age-adjusted | 1 | 1.08 (0.56, 2.08) | 1.00 (0.51, 1.95) | 1.79 (0.88, 3.64) | 0.13 |
| Multivariable[c] | 1 | 1.38 (0.59, 3.22) | 1.37 (0.56, 3.34) | 2.44 (0.93, 6.40) | 0.08 |
| **By stage** | | | | | |
| Local/regional | | | | | |
| Age-adjusted | 1 | 1.11 (0.82, 1.51) | 1.07 (0.78, 1.48) | 1.33 (0.97, 1.81) | 0.08 |
| Multivariable[c] | 1 | 1.01 (0.71, 1.44) | 1.01 (0.70, 1.45) | 1.23 (0.86, 1.76) | 0.24 |
| Metastatic | | | | | |
| Age-adjusted | 1 | 0.84 (0.37, 1.90) | 0.41 (0.16, 1.04) | 1.12 (0.46, 2.73) | 0.82 |
| Multivariable[c] | 1 | 1.66 (0.56, 4.92) | 0.55 (0.18, 1.73) | 2.32 (0.69, 7.83) | 0.30 |

[a]ORs (95% CIs) of CRC were determined by conditional logistic regression.

[b]Medians for each quartile used in trend test: quartile 1 = 7.0 µmol/L, quartile 2 = 8.6 µmol/L, quartile 3 = 9.8 µmol/L, and quartile 4 = 11.8 µmol/L.

[c]Multivariable analyses were adjusted for age, baseline BMI, pack-years of smoking, moderate or strenuous physical activity (min/wk), use of postmenopausal-hormone-therapy, history of colonoscopy, RBC folate, plasma PLP, plasma vitamin B12, and plasma homocysteine.

**Table 3**

ORs (95% CIs) of CRC by quartile of plasma betaine[a]

| | Quartiles of betaine (μmol/L) | | | | |
| --- | --- | --- | --- | --- | --- |
| | 1 (≤18.8) | 2 (>18.8–26.6) | 3 (>26.6–34.0) | 4 (>34.0) | P-trend[b] |
| *n* | 413 | 464 | 417 | 376 | |
| **All participants** | | | | | |
| Age-adjusted | 1 | 1.32 (1.01, 1.73) | 1.02 (0.77, 1.36) | 0.93 (0.70, 1.24) | 0.29 |
| Multivariable[c] | 1 | 1.03 (0.75, 1.43) | 0.74 (0.52, 1.06) | 0.68 (0.47, 0.99) | 0.01 |
| **By tumor site** | | | | | |
| Proximal | | | | | |
| Age-adjusted | 1 | 1.33 (0.95, 1.87) | 1.07 (0.74, 1.54) | 0.80 (0.55, 1.17) | 0.16 |
| Multivariable[c] | 1 | 1.26 (0.84, 1.89) | 0.87 (0.55, 1.38) | 0.69 (0.43, 1.10) | 0.05 |
| Distal | | | | | |
| Age-adjusted | 1 | 1.51 (0.81, 2.81) | 1.25 (0.67, 2.36) | 1.12 (0.58, 2.16) | 0.95 |
| Multivariable[c] | 1 | 0.89 (0.37, 2.11) | 0.82 (0.33, 2.02) | 0.63 (0.23, 1.73) | 0.32 |
| Rectal | | | | | |
| Age-adjusted | 1 | 1.44 (0.74, 2.80) | 0.65 (0.33, 1.27) | 1.13 (0.60, 2.14) | 0.71 |
| Multivariable[c] | 1 | 1.02 (0.43, 2.42) | 0.35 (0.13, 0.96) | 0.61 (0.22, 1.70) | 0.16 |
| **By stage** | | | | | |
| Local/regional | | | | | |
| Age-adjusted | 1 | 1.31 (0.98, 1.74) | 0.91 (0.67, 1.23) | 0.93 (0.67, 1.28) | 0.23 |
| Multivariable[c] | 1 | 1.01 (0.71, 1.44) | 0.64 (0.43, 0.96) | 0.64 (0.42, 0.99) | 0.009 |
| Metastatic | | | | | |
| Age-adjusted | 1 | 1.34 (0.57, 3.15) | 2.13 (0.87, 5.25) | 0.91 (0.45, 1.85) | 0.55 |
| Multivariable[c] | 1 | 0.97 (0.33, 2.82) | 1.91 (0.61, 5.95) | 0.85 (0.31, 2.37) | 0.70 |

[a] ORs (95% CIs) of CRC were determined by conditional logistic regression.

[b] Medians for each quartile used in trend test: quartile 1 = 14.4 μmol/L, quartile 2 = 22.8 μmol/L, quartile 3 = 29.9 μmol/L, and quartile 4 = 39.1 μmol/L.

[c] Multivariable analyses were adjusted for age, baseline BMI, pack-years of smoking, moderate or strenuous physical activity (min/wk), use of postmenopausal-hormone-therapy, history of colonoscopy, RBC folate, plasma PLP, plasma vitamin B12, and plasma homocysteine.

**Table 4**

ORs (95% CIs) of CRC by quartile of plasma betaine:choline ratio[a]

| | Quartiles of betaine:choline ratio | | | | |
| --- | --- | --- | --- | --- | --- |
| | 1 (≤2.0) | 2 (>2.0–2.8) | 3 (>2.8–3.8) | 4 (>3.8) | P-trend[b] |
| *n* | 416 | 446 | 436 | 372 | |
| **All participants** | | | | | |
| Age-adjusted | 1 | 1.12 (0.85, 1.48) | 1.08 (0.83, 1.41) | 0.79 (0.59, 1.05) | 0.08 |
| Multivariable[c] | 1 | 0.83 (0.60, 1.15) | 0.87 (0.62, 1.22) | 0.56 (0.39, 0.82) | 0.004 |
| **By tumor site** | | | | | |
| Proximal | | | | | |
| Age-adjusted | 1 | 1.26 (0.88, 1.79) | 1.09 (0.77, 1.55) | 0.74 (0.51, 1.09) | 0.08 |
| Multivariable[c] | 1 | 1.12 (0.73, 1.70) | 0.98 (0.63, 1.53) | 0.66 (0.41, 1.06) | 0.049 |
| Distal | | | | | |
| Age-adjusted | 1 | 0.90 (0.48, 1.69) | 1.07 (0.61, 1.87) | 0.83 (0.43, 1.60) | 0.76 |
| Multivariable[c] | 1 | 0.53 (0.24, 1.18) | 0.86 (0.40, 1.84) | 0.45 (0.19, 1.10) | 0.24 |
| Rectal | | | | | |
| Age-adjusted | 1 | 1.06 (0.55, 2.06) | 0.94 (0.51, 1.73) | 0.75 (0.39, 1.41) | 0.32 |
| Multivariable[c] | 1 | 0.56 (0.22, 1.43) | 0.45 (0.18, 1.13) | 0.27 (0.10, 0.78) | 0.02 |
| **By stage** | | | | | |
| Local/regional | | | | | |
| Age-adjusted | 1 | 1.17 (0.86, 1.58) | 1.04 (0.78, 1.38) | 0.74 (0.54, 1.02) | 0.04 |
| Multivariable[c] | 1 | 0.88 (0.61, 1.27) | 0.81 (0.56, 1.18) | 0.50 (0.33, 0.76) | 0.001 |
| Metastatic | | | | | |
| Age-adjusted | 1 | 0.81 (0.38, 1.75) | 1.05 (0.49, 2.24) | 0.95 (0.43, 2.10) | 0.95 |
| Multivariable[c] | 1 | 0.55 (0.20, 1.54) | 0.80 (0.27, 2.32) | 0.79 (0.25, 2.50) | 0.98 |

[a] ORs (95% CIs) of CRC were determined by conditional logistic regression.

[b] Medians for each quartile used in trend test: quartile 1 = 1.6, quartile 2 = 2.4, quartile 3 = 3.2 and quartile 4 = 4.4.

[c] Multivariable analyses were adjusted for age, baseline BMI, pack-years of smoking, moderate or strenuous physical activity (min/wk), use of postmenopausal-hormone-therapy, history of colonoscopy, RBC folate, plasma PLP, plasma vitamin B12, and plasma homocysteine.

**Table 5**

ORs (95% CIs) of CRC by quartile of plasma TMAO[a]

| | Quartiles of TMAO (μmol/L) | | | | |
|---|---|---|---|---|---|
| | 1 (≤2.6) | 2 (>2.6–3.7) | 3 (>3.7–5.6) | 4 (>5.6) | P-trend[b] |
| n | 358 | 435 | 426 | 451 | |
| All participants | | | | | |
| Age-adjusted | 1 | 1.67 (1.25, 2.23) | 1.55 (1.16, 2.07) | 1.78 (1.32, 2.40) | 0.005 |
| Multivariable[c] | 1 | 1.90 (1.36, 2.64) | 1.47 (1.06, 2.05) | 1.65 (1.17, 2.34) | 0.13 |
| By tumor site | | | | | |
| Proximal | | | | | |
| Age-adjusted | 1 | 2.06 (1.40, 3.03) | 2.06 (1.39, 3.04) | 1.93 (1.31, 2.83) | 0.04 |
| Multivariable[c] | 1 | 2.37 (1.52, 3.70) | 1.92 (1.23, 3.00) | 1.69 (1.09, 2.63) | 0.42 |
| Distal | | | | | |
| Age-adjusted | 1 | 1.50 (0.77, 2.92) | 1.20 (0.63, 2.27) | 1.54 (0.78, 3.06) | 0.41 |
| Multivariable[c] | 1 | 1.96 (0.86, 4.48) | 1.19 (0.56, 2.53) | 1.69 (0.73, 3.90) | 0.59 |
| Rectal | | | | | |
| Age-adjusted | 1 | 1.03 (0.53, 1.98) | 0.99 (0.52, 1.89) | 2.26 (1.06, 4.79) | 0.02 |
| Multivariable[c] | 1 | 1.42 (0.62, 3.28) | 1.20 (0.53, 2.72) | 3.38 (1.25, 9.16) | 0.02 |
| By stage | | | | | |
| Local/regional | | | | | |
| Age-adjusted | 1 | 1.59 (1.16, 2.19) | 1.56 (1.13, 2.14) | 1.78 (1.28, 2.46) | 0.008 |
| Multivariable[c] | 1 | 1.90 (1.31, 2.74) | 1.46 (1.00, 2.11) | 1.78 (1.21, 2.60) | 0.08 |
| Metastatic | | | | | |
| Age-adjusted | 1 | 2.81 (1.23, 6.41) | 1.61 (0.78, 3.32) | 2.26 (0.96, 5.31) | 0.17 |
| Multivariable[c] | 1 | 3.63 (1.29, 10.23) | 2.27 (0.86, 5.96) | 2.09 (0.63, 6.97) | 0.47 |

[a] ORs (95% CIs) of CRC were determined by conditional logistic regression.

[b] Medians for each quartile used in trend test: quartile 1 = 2.0 μmol/L, quartile 2 = 3.1 μmol/L, quartile 3 = 4.5 μmol/L, and quartile 4 = 8.1 μmol/L.

[c] Multivariable analyses were adjusted for age, baseline BMI, pack-years of smoking, moderate or strenuous physical activity (min/wk), use of postmenopausal-hormone-therapy, history of colonoscopy, RBC folate, plasma PLP, plasma vitamin B12, and plasma homocysteine.

**Table 6**

ORs (95% CIs) of CRC associated with quartiles of plasma TMAO by vitamin B12 status[a]

| | Quartiles of TMAO (µmol/L)[b] | | | | |
| --- | --- | --- | --- | --- | --- |
| | 1 (≤2.6) | 2 (>2.6–3.7) | 3 (>3.7–5.6) | 4 (>5.6) | P-interaction[c] |
| **Vitamin B12 status** | | | | | |
| Age-adjusted | | | | | 0.0007 |
| Multivariable[d] | | | | | 0.003 |
| Low B12 (≤505 pg/mL) | | | | | |
| no. of cases | 77 | 107 | 122 | 153 | |
| Age-adjusted | 1 | 1.74 (1.17, 2.58) | 2.01 (1.35, 2.98) | 2.49 (1.68, 3.67) | |
| Multivariable[d] | 1 | 2.00 (1.30, 3.06) | 2.06 (1.34, 3.17) | 2.44 (1.59, 3.75) | |
| High B12 (>505 pg/mL) | | | | | |
| no. of cases | 71 | 122 | 95 | 86 | |
| Age-adjusted | 1 | 1.45 (0.97, 2.18) | 1.11 (0.73, 1.69) | 1.00 (0.66, 1.53) | |
| Multivariable[d] | 1 | 1.49 (0.96, 2.32) | 0.98 (0.63, 1.55) | 0.92 (0.58, 1.47) | |

[a] ORs (95% CIs) of CRC were determined by unconditional logistic regression due to case-control matching being broken in these subset analyses. Models were additionally adjusted for ethnicity and time to diagnosis.

[b] Medians for each quartile: quartile 1 = 2.0 µmol/L, quartile 2 = 3.1 µmol/L, quartile 3 = 4.5 µmol/L, and quartile 4 = 8.1 µmol/L.

[c] P value for test of interaction between TMAO (as an ordinal variable) and plasma B-vitamin status.

[d] Multivariable analyses were adjusted for days to CRC diagnosis, ethnicity, age, baseline BMI, pack-years of smoking, moderate or strenuous physical activity (min/wk), use of postmenopausal-hormone-therapy, history of colonoscopy, RBC folate, plasma PLP, and plasma homocysteine.

**Table 7**

ORs (95% CIs) of CRC associated with quartiles of plasma betaine by FA fortification periods[a]

| | Quartiles of betaine (μmol/L)[b] | | | | |
|---|---|---|---|---|---|
| | 1 (≤18.8) | 2 (>18.8–26.6) | 3 (>26.6–34.0) | 4 (>34.0) | P-interaction[c] |
| Fortification period | | | | | |
| Age-adjusted | | | | | 0.04 |
| Multivariable[d] | | | | | 0.08 |
| Pre-fortification | | | | | |
| no. of cases | 50 | 65 | 49 | 38 | |
| Age-adjusted | 1 | 1.45 (0.84, 2.51) | 0.85 (0.49, 1.48) | 0.73 (0.41, 1.29) | |
| Multivariable[d] | 1 | 1.06 (0.55, 2.01) | 0.65 (0.32, 1.31) | 0.46 (0.22, 0.98) | |
| Peri-fortification | | | | | |
| no. of cases | 107 | 147 | 116 | 89 | |
| Age-adjusted | 1 | 1.43 (0.99, 2.07) | 0.98 (0.67, 1.42) | 0.78 (0.53, 1.15) | |
| Multivariable[d] | 1 | 1.10 (0.72, 1.67) | 0.74 (0.47, 1.15) | 0.64 (0.39, 1.04) | |
| Post-fortification | | | | | |
| no. of cases | 44 | 48 | 38 | 44 | |
| Age-adjusted | 1 | 1.09 (0.62, 1.92) | 1.39 (0.74, 2.60) | 1.58 (0.85, 2.91) | |
| Multivariable[d] | 1 | 0.88 (0.46, 1.69) | 0.87 (0.41, 1.86) | 0.97 (0.45, 2.06) | |

[a] ORs (95% CIs) of CRC were determined by unconditional logistic regression due to case-control matching being broken in these subset analyses. Models were additionally adjusted for ethnicity and time to diagnosis.

[b] Medians for each quartile: quartile 1 = 14.4 μmol/L, quartile 2 = 22.8 μmol/L, quartile 3 = 29.9 μmol/L, and quartile 4 = 39.1 μmol/L.

[c] P value for test of interaction between betaine (as an ordinal variable) and FA fortification periods.

[d] Multivariable analyses were adjusted for days to CRC diagnosis, ethnicity, age, baseline BMI, pack-years of smoking, moderate or strenuous physical activity (min/wk), use of postmenopausal-hormone-therapy, history of colonoscopy, RBC folate, plasma PLP, plasma vitamin B12, and plasma homocysteine.